Conference News

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

Featured

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

Patients with obesity randomized to the drug had less subclinical leaflet thrombosis and paravalvular leak than controls.

By L.A. McKeown

March 19, 2026

Latest Conference News

See All

What’s Going to Be Hot at ACC 2026

By Michael O'Riordan

March 20, 2026
Now Published: LAAO Doesn’t Match Medical Therapy for High-risk AF Patients in CLOSURE-AF

By Caitlin E. Cox

March 18, 2026
PARTNER 3: TAVI and SAVR Matched for Health Status at 7 Years

By L.A. McKeown

March 17, 2026
CARPOOL Radial Access as Good as Femoral in PAD Procedures

By L.A. McKeown

March 16, 2026
SOLVE-TAVI: Patient Sex, for the Most Part, Doesn’t Sway Outcomes by Valve Type

By L.A. McKeown

March 16, 2026
AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis

By L.A. McKeown

March 11, 2026

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.